| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Deslanoside (Desacetyllanatoside C) is tricanoside C's metabolite[4]. Deslanoside lowers heart rate, raises forearm blood flow and cardiac index, and considerably lowers tibial muscle sympathetic nerve activity, which is a measure of the activity of the centrally controlled sympathetic nervous system [1].
|
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Low gastrointestinal absorption (40%). Biological Half-Life 36 hours |
| Toxicity/Toxicokinetics |
Protein Binding
20% |
| References | |
| Additional Infomation |
Deslanoside is a cardiac glycoside formed by replacing the acetoxy group with a hydroxyl group in lanatoside C. It has antiarrhythmic, cardiotonic, metabolite, and EC 3.6.3.9 (Na(+)/K(+)-transporter ATPase) inhibitory effects. It is a 14β-hydroxysteroid, a 12β-hydroxysteroid, a cardiac glycoside, and a tetrasaccharide derivative. Deslanoside C is a cardiac glycoside extracted from the leaves of foxglove (Digitalis lanata). It has been reported that lanatosides are present in green foxglove (Digitalis viridiflora), purple foxglove (Digitalis purpurea), and other organisms with relevant data. Deslanoside C is a cardiac glycoside extracted from the leaves of foxglove (Digitalis lanata). Indications: Used for the treatment and control of congestive heart failure, arrhythmias, and heart failure. Mechanism of Action Digoxin inhibits the Na-K-ATPase membrane pump, leading to increased intracellular sodium and calcium ion concentrations. Increased intracellular calcium ion concentration may promote the activation of contractile proteins (such as actin and myosin). Digoxin also affects cardiac electrical activity, increasing the slope of phase 4 depolarization, shortening the action potential duration, and reducing the maximum diastolic potential. Pharmacodynamics Digoxin is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias caused by reentry mechanisms, as well as to control ventricular rate in the treatment of chronic atrial fibrillation.
|
| Molecular Formula |
C47H74O19
|
|---|---|
| Molecular Weight |
943.09
|
| Exact Mass |
942.482
|
| CAS # |
17598-65-1
|
| PubChem CID |
28620
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Melting Point |
220-235ºC
|
| Index of Refraction |
1.620
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
66
|
| Complexity |
1760
|
| Defined Atom Stereocenter Count |
26
|
| SMILES |
C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O
|
| InChi Key |
OBATZBGFDSVCJD-LALPQLPRSA-N
|
| InChi Code |
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
|
| Chemical Name |
3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
|
| Synonyms |
Lekozid; Ceglunat; Deslanosid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~106.04 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0603 mL | 5.3017 mL | 10.6034 mL | |
| 5 mM | 0.2121 mL | 1.0603 mL | 2.1207 mL | |
| 10 mM | 0.1060 mL | 0.5302 mL | 1.0603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
